Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

AI eye exams accurately identify heart disease risk during routine visits

30

Mar 2026

AI eye exams accurately identify heart disease risk during routine visits

A new system that uses artificial intelligence (AI) to assess cardiovascular risk based on images of the eye captured during eye exams demonstrated strong correlation with a standard cardiovascular risk assessment, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

Triglyceride-lowering drug olezarsen fails to reduce arterial plaque

30

Mar 2026

Triglyceride-lowering drug olezarsen fails to reduce arterial plaque

Despite experiencing significant reductions in triglycerides, patients with triglycerides over 150 mg/dL and a high risk of atherosclerosis did not experience any significant change in the amount of non-calcified plaque in their coronary arteries after taking the triglyceride-lowering drug olezarsen, in a one-year sub-study presented at the American College of Cardiology's Annual Scientific Session.

Culturally tailored food programs significantly lower blood pressure in minority adults

30

Mar 2026

Culturally tailored food programs significantly lower blood pressure in minority adults

Black and Hispanic adults with high blood pressure (hypertension) who received a culturally tailored food-based intervention with dietitian coaching experienced a significant drop in blood pressure compared with those who received an equivalent amount of fresh produce without additional supports, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

Digoxin found safe to use in young patients with rheumatic heart disease

30

Mar 2026

Digoxin found safe to use in young patients with rheumatic heart disease

Patients with rheumatic heart disease who took the heart failure drug digoxin were 18% less likely to die or experience new-onset or worsening heart failure during a two-year follow-up compared with those who received a placebo, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

Discontinuing beta-blockers after heart attack found to be safe for low-risk patients

30

Mar 2026

Discontinuing beta-blockers after heart attack found to be safe for low-risk patients

Among stable, relatively low-risk patients who had previously suffered a heart attack, discontinuing beta-blockers after at least one year was found to be non-inferior, or comparable, to continuing beta-blockers in terms of death, another heart attack or hospitalization for heart failure, according to a study presented at the American College of Cardiology's Annual Scientific Session.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.